March 02, 2023 — 06:22 am EST

      Written by
                        RTTNews.com for                             
        




RTTNews ->


(RTTNews) - Essential medicines company Amneal Pharmaceuticals, Inc. (AMRX) announced Thursday that the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for naloxone hydrochloride nasal spray, USP, 4mg, which is the generic version of Narcan and is used in the treatment of a known or suspected opioid overdose emergency.
Naloxone hydrochloride nasal spray is a critical tool in addressing the opioid public health emergency across the United States
According to IQVIA, U.S. annual sales for this product for the 12 months ended December 2022 were $318 million. In addition, there are significant volumes of the product purchased directly by U.S. states. 
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

© 2023, Nasdaq, Inc. All Rights Reserved.










To add symbols:


These symbols will be available throughout the site during your session.
To add symbols:


These symbols will be available throughout the site during your session.